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ABSTRACT
Photodynamic therapy (PDT) and photodynamic inactivation (PDI) are technologies that utilize visible light and photosensitizers
(PS) to inactivate cells. PDT is currently in use for the treatment of several types of tumors. Although cancer has been successfully treated
with PS and light, antimicrobial PDI is emerging as a new treatment modality for bacterial infections due to its effectiveness and less
likelihood of inducing bacterial resistance. Resistance to therapy is in part due to the ability of the organisms to form a biofilm, which
provides a microenvironment that protects the microorganism from antibiotics and attack by the host’s immune system. In vitro, PDI
nonetheless was shown to be effective against Gram-negative and Gram-positive bacteria. When used in-vivo however, several factors
were shown to influence and diminish the effectiveness of PDI, such as aggregation of PS and plasma protein binding. To circumvent
these factors, different nanotechnology platforms were used to enhance the photodynamic inactivation efficacy, such as liposomes,
micelles and nanoparticles, by reducing the PS aggregation and albumin binding to the PS. In general, studies have shown that photodynamic inactivation efficacy could be enhanced when suitable nanocarriers are used to deliver the PS.
Key words: photodynamic inactivation, liposome, micelle, nanoparticles

INTRODUCTION
I. Photodynamic Therapy (PDT)
The phototoxicity of chemical compounds towards
microorganisms was first published at the turn of the 20th
century. Oskar Raab observed that the toxicity of acridine
hydrochloride against Paramecia caudatum was dependent on the amount of light incident on the experimental
mixture(1). von Tappeiner and Jadblauer reported that the
observed toxic effect in the presence of light was not attributed to heat. In 1904, experiments performed to exclude the
direct influence of light led von Tappeiner to coin the term
photodynamic reaction(1), which later became known as PDT.
PDT represents a well-established therapeutic modality,
which was originally developed and recently approved for
the treatment of a variety of solid tumors(2). It involves the
systemic administration of the photosensitizer (PS), such as
phenothiazines(3), prophyrins(4), chlorins(5) and phthalocyanines(6), followed by photoactivation of PS at the disease site
with light of specific wavelength(7). The three fundamental
requirements for PDT are therefore oxygen, light source and
* Author for correspondence. Tel: +886-2-27361661 ext. 5203;
Fax: +886-2-27390082; E-mail: tmtsai00@tmu.edu.tw

PS. Each factor is harmless by itself, but their combination
can produce cytotoxic agents, which may be used to kill
tumor cells or pathogenic microorganisms.
In order to be effective, the PS ideally should be selective to tumor tissues and should preferentially localize in the
rapidly growing tumor cells before they release the highly
reactive singlet oxygen species (ROS)(2). Due to its short
lifetime, singlet oxygen intracellular diffusion distance is not
more than 0.01 - 0.02 µm and therefore its direct action is
dependent on and limited to the intracellular structure where
the sensitizer is localized(8). For example, PSs localized in
the mitochondria induce apoptosis very rapidly(9), where
cytochrome c release is one of the best-known apoptotic
events after photosensitization(10). Furthermore, despite its
significant advantages, the biodistribution of the PS(11) is
limited. In addition, phototoxicity to the skin, due mainly
to the hydrophobicity and non-selectivity of PS, is another
considerable limitation(12).
The mechanism by which PS works is illustrated in
Figure 1. PS in a singlet state at the lowest or ground state
energy level (S0) may absorb a photon from light of a specific
wavelength to enter an excited state (S1). When excited to a
triplet state, the photosensitizer may undergo two kinds of
reactions. In type I reaction, the PS can react directly with
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a substrate, such as the cell membrane or a molecule, and
transfer a proton or an electron to form a radical anion or
radical cation. In type II reaction, the PS in the excited triplet
state would directly form highly reactive singlet oxygen.
Both type I and type II reactions can occur simultaneously.
The ratio between these reactions depends on the type of PS
used and the concentrations of the substrate and oxygen(13).
II. Photodynamic Inactivation (PDI) of Bacteria
Since the middle of the last century, antimicrobial PDI
was overlooked by the discovery of antibiotics. In the last
decade, the worldwide increase in antibiotic resistance has
driven research into the development of new antimicrobial
strategies(14). A relatively novel antimicrobial application of
PDI has been made possible by the preparation of PS, whose
molecule is engineered to promote a very fast interaction
with bacterial cells, hence a highly preferential inactivation
of pathogenic agents in comparison with the main constituents of host tissues, such as fibroblasts and keratinocytes(15).
These findings paved the way to the use of PDI for the treatment of localized and drug resistant microbial infections(16).
In the 1990s, it was observed that there was a fundamental difference in susceptibility to PDI between Grampositive and Gram-negative bacteria (Table 1)(17,18). It was
found that, in general, neutral or anionic PS molecules efficiently bind to and photodynamically inactivate Gram-positive bacteria, whereas they bind only to the outer membrane
of Gram-negative bacterial cells rendering them less effective(19). The high susceptibility of Gram-positive species
could be explained by their physiology, as their cytoplasmic
membrane is surrounded by a relatively porous layer of peptidoglycan and lipoteichoic acid that allows PS to cross(19). The
cell envelope of Gram-negative bacteria, however, consists
of an inner cytoplasmic membrane and an outer membrane
that are separated by a peptidoglycan-containing periplasm
(Figure 2)(19). The outer membrane forms a physical and

functional barrier between the cell and its environment. In
the outer membrane, different proteins are present; some
of which function as pores to allow passage of nutrients,
whereas others have an enzymatic function or are involved
in maintaining the structural integrity of the outer membrane
and the shape of the bacteria (Figure 2).
Several approaches have been attempted to potentiate
the efficacy of PDI against Gram-negative bacteria. Nitzan
and coworkers used polycationic peptide, polymyxin B
nonapeptide (PMBN) to increase the outer membrane
permeability of Gram-negative bacteria and allow the PS,
that are normally excluded from the cell, to penetrate into the
bacterial cell where illumination-generated reactive oxygen
species can result in fatal bacterial damage(20). PMBN does
not release lipopolysaccharide (LPS) from the cells. On the
contrary, it ‘expands’ the outer leaflet of the membrane,
allowing PS such as deuteroporphyrin (DP) to penetrate and
induce a PDI effect on E. coli and P. aeruginosa(20). This
method was also used to kill a multi-antibiotic resistant strain
of A. baumannii. Nitzan et al. speculated that the interaction
and bonding between PMBN and DP in solution facilitated
PS penetration into the microorganism as DP seemed to
work much better in concert with PMBN than many other
PS, including porphyrins, phthalocyanines and merocyanine 540(21). It was also observed that the growth medium
of the bacteria made a difference to their susceptibility to
PDI, with the high protein nutrient broth leading to less
killing, compared to the low protein nutrient broth medium.
Furthermore, it was noted that the type of protein present in
the medium, as well as its concentration, made a difference
to the susceptibility of the bacteria.
A second approach involved the use of PS molecules
with an intrinsic positive charge. Wilson and coworkers used
Toluidine Blue O to study the effect of PDI on a range of
both Gram-positive and Gram-negative bacteria(22). These
studies were mostly concerned with oral bacteria(23), though
PDI was also tested on S. aureus and the Gram-negative
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Figure 1. Jablonski diagram showing the energy transferred from photosensitizers to molecular oxygen.
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Table 1. List of photosensitizers and Gram-positive and Gram-negative bacteria for which in vitro photoinactivation studies were performed
Species (Gram status)

Photosensitizers

Staphylococcus aureus (+)

Methylene blue
Photosens
Toluidine blue
Hematoporphyrin
Photofrin
m-THPC
Hypericin
Malachite green isothiocyanate
Cationic, neutral and anionic Tetraphenylporphyrins
Rose bengal
Methylene blue
Toluidine blue
Photosens
Methylene blue

(78,79)
(80)
(78,81)
(82)
(83)
(83)
(83)
(84)
(85)
(86)
(79)
(81)
(80)
(79)

Methylene blue(78,79)
Toluidine blue
Zinc pyridiniumphthalocyanine

(78,79)
(78)
(87)

Staphylococcus epidermidis (+)

Streptococcus pyogenes (+)
Streptococcus pneumonia (+)
Enterococcus seriolicida (+)
Enterococcus hirae (+)

References

Bacillus subtilis (-)

Cationic, neutral and anionic Tetraphenylporphyrins
ALA
Zinc phthalocyanine tetrasulfonate
Methylene blue
Toluidine blue
Hematoporphyrin derivative

(85)
(88)
(88)
(78)
(78)
(89)

Streptococcus faecalis (-)

Hematoporphyrin derivative

(89)

Enterococcus faecalis (+)

Deinococcus radiodurans (-)

Rose bengal

(90)

Pseudomonas aeruginosa (-)

Acinetobacter baumannii (-)

Photosens
Methylene blue
Toluidine blue
Zinc pyridiniumphthalocyanine
Rose bengal
N-Alkylpyridylporphyrins
Cationic hydrophilic porphyrin
Cationic, neutral and anionic Tetraphenylporphyrins
ALA
Photosens
Zinc pyridiniumphthalocyanine
Thiazines
Xanthenes
Acridines
Phenazines
Methylene blue
Toluidine blue
Zinc phthalocyanine tetrasulfonate
Cationic hydrophilic porphyrin

(80)
(78)
(78)
(87)
(86)
(91)
(92)
(85)
(88)
(80)
(87)
(93)
(93)
(93)
(93)
(78)
(78)
(88)
(92)

Corynebacterium minutissimum (-)

Methylene blue

(79)

Haemophilus influenza (-)

Methylene blue
Toluidine blue
ALA
Methylene blue

(78)
(78)
(94)
(79)

Escherichia coli (-)

Propionibacterium acnes (-)
Proteus mirabilis (-)

Photosens

(80)

Helicobacter pylori (-)

Hematoporphyrin derivative

(95)

Salmonella typhimurium (-)

Rose bengal

(96)
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Figure 2. Diagrams illustrating the differences in the membrane structure between Gram-positive (A) and Gram-negative bacteria (B).

H. pylori(23,24). It was observed that the growth phase of
the bacteria did not influence their susceptibility to PDI,
whereas the presence of serum in the medium decreased the
killing(25). In another study, washing the loosely bound PS
from the cells before illumination was found to decrease the
killing. This could be attributed to the limited photodamage
caused by the first dose of light, which in turn may not have
been sufficient to allow further penetration of bound PS(4).
There are several reports on PDI of Gram-negative
bacteria in which it was clear that PS does not have to penetrate
the bacterium to be effective or even come into contact with
the cells(18). According to these reports, if singlet oxygen can
be generated in sufficient quantities near to the bacterial outer
membrane, it will be able to diffuse into the cell to inflict
damage on vital structures(26). In one set of studies, bacteria
were separated from the PS by a layer of moist air. Singlet
oxygen in the gas phase was generated and allowed to diffuse
across the gap before contacting the bacteria(27). Nonetheless,
Gram-negative species remained harder to kill than Grampositive bacteria, where the intracellular content of carotenoids
was found to protect the bacteria from photoinactivation.
III. Mechanisms of PDI-Induced Damage
Two mechanisms were proposed to account for the
lethal damage caused to bacteria by PDI: (i) DNA damage
and (ii) damage to the cytoplasmic membrane, allowing
leakage of cellular contents or inactivation of membrane
transport systems and enzymes(18). Evidence suggests that
treatment of bacteria with various PS, light and singlet
oxygen leads to DNA damage. Cleavage in both single- and

double stranded DNA, and the disappearance of the plasmid
supercoiled fraction have been detected in both Grampositive and Gram-negative species after PDI treatment with
a wide range of PS structural types(28,29). The damage may
be repaired by various DNA repairing systems(30). Nonetheless, various authors have also concluded that although DNA
damage occurs, it may not be the prime cause of bacterial
cell death. Disturbance of cell-wall synthesis and the appearance of a multilamellar structure near the septum of dividing
cells, along with loss of potassium ions from the cells were
reported by Nitzan et al.(20)

LIMITATIONS OF PDT/PDI
The principle of PDT and PDI is based on the combined
use of a PS and low-intensity visible light of an appropriate
wavelength(31). After light irradiation, activated PS generates
cytotoxic reactive oxygen species that induce a bactericidal
effect. Although the possibility to inactivate microbes by
PDI has been known for more than 10 decades(32), it is only
recently that this modality gained attention as a viable tool
to eradicate infectious pathogens(18). The main advantage
of PDI is that bacteria can be eradicated almost instantly
while avoiding damage to adjacent host tissues. PDI is effective against antibiotic-resistant and antibiotic-susceptible
bacteria, without inducing resistance even after repeated
photosensitization.
Despite the frequent clinical use of PDT for the treatment of several malignancies(33), the use of PDI to inactivate
microorganisms is still in the research phase(34). This is in
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part due to the fact that PDI of Gram-negative bacteria with
first generation PS, such as the anionic hematoporphyrin, had
to be mediated by membrane permeabilizers, such as ethylenediaminetetraacetic acid or polymyxin nonapeptide(19).
Later it was discovered that cationic porphyrins did not
require membrane permeabilizers in order to successfully
inactivate Gram-negative bacteria(4). It has been demonstrated that Gram-positive and Gram-negative bacteria, and
fungi can be successfully photodynamically inactivated
by a single cationic photosensitizer, for instance 5-phenyl10,15,20-tris(N-methyl-4-pyridyl)porphyrin
(TriP[4])(35)
(36)
or toluidine blue . Furthermore, it has been shown that
both antibiotic-sensitive and resistant strains can be successfully photoinactivated(15,37) without inducing resistance to
photosensitization.
In general, most intravenously administered PS for PDT
or PDI are rapidly cleared from the circulation, although some
of the molecules bind to serum proteins, such as albumin and
low-density lipoprotein (LDL), and remain in circulation for
a longer period(38). Facilitated uptake of LDL-bound PS by
tumor cells expressing a large number of LDL receptors on
their surface has been reported to increase the specificity
of the PS to the tumor cells(38,39). However, LDL-bound PS
can also be taken up by macrophages, which may localize
in the skin, leading to skin hyperphotosensitivity(38,39). To
circumvent this side effect, considerable efforts have been
devoted to the development of new PS that would accumulate
quickly in tumor tissues and could be rapidly cleared from
the skin. One such example is taporfin sodium (Talaporfin),
a second generation PS that shows rapid clearance from the
skin and has been approved for the treatment of early-stage
lung cancers in Japan(40). Nonetheless, while PDT with Talaporfin can reduce skin phototoxicity; the patient is required
to stay in the dark for at least 2 weeks(7).
Other factors, such as the presence of wound fluid, are
expected to influence the antimicrobial activity of PDI. For
example, in many in vitro studies, it was shown that the consistency of the buffer or broth used as a suspending medium
strongly influences the efficacy of antimicrobial PDI(21). The
in vivo efficacy of PDI is further complicated by the fact that
biological membranes seem to be an important target for
many antineoplastic photosensitizer agents(34). Nonetheless,
the significant biomedical applications of PDI could not be
ignored. For example, commonly used implants that have
been developed to assist in the performance and recovery
of physiological functions present a constant risk because of
bacterial colonization and biofilm formation on their surface.
Fortunately, many of the in vivo deficiencies of PDI could
be circumvented with the use of nanocarriers, which will be
discussed in the subsequent sections of this review.

NANOCARRIER-ENCAPSULATED
PHOTOSENSITIZERS FOR PHOTODYNAMIC
THERAPY AND INACTIVATION
Alternatively, nanocarriers for PS delivery may be used

to enhance the efficacy of PDT and PDI. While the use of
long-circulating nanocarriers for PS delivery may seem to
contradict the aforementioned trends in the development of
the new PS(7), these delivery systems will reduce the likelihood of aggregation of the potential PS(31). Encapsulation
techniques that have been used to prevent the formation of
aggregates include liposomes(41), polymeric micelles(42),
nanoparticles(43) and nanofilms. A list of nanocarriers and
photosensitizers that were used in PDI and tested for their
efficacy against Gram-positive, Gram-negative and yeast
microorganisms is given in Table 2.
I. Liposomes
Liposomes (Figure 3A) have been widely investigated
as drug delivery systems due to their structural similarity
to the cell membrane(31). They are versatile and allow for
triggered drug release. For example, drug release can be triggered by near-infrared irradiation of hollow gold liposomes
containing light-sensitive polymeric materials(44). Also,
thermal- and pH-sensitive, as well as enzymatically triggered and receptor-targeted liposomes were developed(45).
From early studies, it has long been known that liposome lysis (or destruction) can be provoked by irradiation
with visible light in the presence of a photosensitizer(46).
These studies aimed at elucidating the mechanisms of photodynamic damage to cells including such significant structural
elements as bilayer lipid membranes(46). Studying the photosensitization and oxidation of both lipid and protein components of biological membranes is important for understanding
basic processes underlying photodynamic therapy(44).
Several approaches have been employed to study the mechanism of photomodification in sensitized membranes(47). Only
few studies, however, included observations of membrane
permeabilization, though the latter is generally accepted to
represent one of the most crucial processes in photodynamic
action leading to cell death(48). In particular, earlier works on
liposomes and planar bilayer lipid membranes (BLM), using
a hematoporphyrin derivative, have shown photosensitized
vesicle disruption(49) and a dramatic increase in planar BLM
conductance resulting in membrane breakdown, provided
that membrane-forming lipids contain double bonds(50).
Liposome-delivered photosensitizers have been adopted
in anti-tumor PDT and proven to yield a more pronounced
and selective targeting of the neoplastic lesion(51). Therefore, liposomes were also investigated for their effect on the
affinity of photosensitizing agents to the bacterial cells and
the efficiency of their photo-induced bacterial killing(16).
Previous studies have shown that the disruption of the bacterial outer wall can be most efficiently achieved by using positively charged liposomes, analogous to the use of polylysine
or polyethyleneimine(16,52). Methicillin-resistant staphylococcus aureus (MRSA) were inactivated by using two noncationic liposome incorporated dyes, hematoporphyrin (HP)
and chlorophyll(16).
Overall, present research suggests that the use of suitable liposomal vesicles as delivery systems for antimicrobial
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Table 2. List of nanocarriers that were loaded with photosensitizers and tested for their in vitro photoactivity against bacteria.
Nanocarriers

Photosensitizers

Species

Liposomes

Xanthomonadin

Xanthomonas oryzae pv. Oryzae strains

(97)

Hematoporphyrin (Hp)
Chlorophylla (Chl)

MRSA

(16)

Phenothiazine
Porphyrin

Gram-positive
Gram-negative

(98)

TDPyP

MRSA

(99)

m-THPC

MRSA

(100)

Hp

MRSA
S. epidermidis
S. pyogenes

(31)

Ce6

S. aureus

(31)

Porphyrin

Multiresistant strains

(101)

Methylene blue (MB)

Staphylococcus aureus
Sarcina lutea
St. epidermidis
Shigella flexneri

(102)

Neutral red (NR)

Staphylococcus aureus
Sarcina lutea
Escherichia coli
Salmonella paraB

(102)

Rose bengal (RB)

St. epidermidis
Shigella flexneri

(102)

Naphthoquinone

Micrococcus luteus

(103)

Escherichia coli

(104)

Hp

MRSA
S. epidermidis
S. pyogenes

(31)

Ce6

S. aureus

(31)

Tri (2,2’-bipyridine) ruthenium

Escherichia coli

(105)

Rose bengal

Escherichia coli

(105)

Methylene blue

S. aureus
P. aeruginosa

(106)

5,10,15,20-Tetrakis (3-hydroxy phenyl)
porphyrin (mTHPP)

S. aureus
P. aeruginosa

(106)

Rose bengal

S. aureus
St. epidermidis

(107)

Micelles

DTC60

Nanoparticles

2+

PDI agents can be useful for the following reasons: (a) noncationic photosensitizers may be used as efficient killing
agents of microbial cells, and (b) the synergic effect of positively charged and highly fluid components of the lipophilic
carrier facilitates uptake by microbial cells and enhances its
overall photoactivity. A significant challenge to liposome
research is that encapsulating drugs in liposomes is not
simple and the composition of an optimal formula can only
be obtained through tedious experimental trials(31). In cancer
research, for example, many studies do not favor liposomes
as a delivery system because phospholipids are expensive,
inherently unstable, and the preparation of liposomes is

References

difficult to scale up. In fact, in some applications, less expensive starting materials, such as polymers, can be used instead
of phospholipids to encapsulate drugs(53).
II. Micelles
Micelles are nanosized, aqueous self-aggregates of
amphiphilic molecules with a hydrophobic core, which are
capable of solubilizing nonpolar molecules(54). Therefore,
they are attractive carriers for poorly water soluble therapeutic drugs. Micelles composed of Cremophor-EL, Tween80, etc. have been used in preclinical and clinical studies
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Figure 3. Schematic illustration of liposomes loaded with (A) drugs and (B) polymeric micelles as intelligent nanocarriers for drug delivery,
with or without peglation.

for the delivery of PS. However, such micelles disassemble
easily upon dilution and are known to be associated with
allergic reactions.
An improvement over the surfactant-based micelles,
in terms of safety and efficiency, are the polymeric drug
carriers, which are made up of biocompatible, hydrophobichydrophilic copolymers (e.g., poloxamers, ploxamines,
pluronics, etc.) Over the past decade, polymeric drug carriers
including polymer-drug conjugates and polymeric micelles
have been proven useful in drug delivery(55) and are being
increasingly investigated in the preclinical stage for PDT
and PDI. In particular, polymeric micelles (Figure 3B) are
currently recognized as one of the most promising modalities of drug delivery(56). They are potent nanocarriers for
site-specific drug delivery, which has been shown in several
clinical trials(57).
Polymeric micelles are characterized by a unique coreshell architecture in which an inner core, serving as a nanocontainer of hydrophobic drugs, is surrounded by an outer
shell of hydrophilic polymers, such as poly(ethylene glycol)
(PEG) (Figure 3C). It is well known that block copolymers
with amphiphilic character spontaneously assemble into
polymeric micelles with a diameter of several tens of nanometers in aqueous media(58). These systems have demonstrated longevity in the bloodstream and effective tumor
accumulation after their systemic administration(57,59). The
biocompatibility of polymeric micelles and their capacity to

avoid renal exclusion and their reduced uptake/degradation
by the reticuloendothelial system allow for their prolonged
systemic circulation time. Drugs encapsulated within polymeric micelles usually exhibit higher passive accumulation
in tumors compared to free drugs with reduced distribution
in non-targeted areas. This passive accumulation is due to
the enhanced permeability and retention effect (EPR) associated with tumor tissues. Furthermore, polymeric micelles
have several advantages, such as simple preparation, efficient
drug loading without chemical modification of the parent
drug, and controlled drug release(60). Besides, hydrophobic
and/or electrostatic interaction between charged block copolymers and oppositely-charged macromolecules has allowed
the formation of unique core-shell nanoparticles, which were
termed “polyion complex (PIC) micelles”(61).
Ionic dendrimer photosensitizers, another example of a
miceller system in which the core of porphyrin or phthalocyanine is surrounded by large dendritic wedges, were developed
to solve the inherent problems with conventional PSs(62). It is
assumed that dendrimer photosensitizers elicit effective ROS
production even at extremely high concentrations because
the dendritic wedges sterically prevent or weaken aggregation of the center dye molecules(63). Also, ionic groups on
the dendrimer periphery allow their stable incorporation into
polyion complex (PIC) micelles through the electrostatic
interaction with oppositely charged poly(ethylene glycol)polyelectrolyte block copolymers(62,63).
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III. Nanoparticles
Various delivery systems have been tested in preclinical studies(64). Of these are the molecular Drug Delivery
Systems (DDS) that have been developed as a way to deliver
photosensitizers to the target tumor(65). Photoimmunotargeting may use monoclonal antibodies that recognize tumor
antigens(66) or ligands against receptors that are upregulated
in tumor cells(67). General strategies for the delivery of phtosensitizers via the molecular DDS was reviewed by Konan et
al.(67) and Wang et al.(68)
In general, liposomes and immunoliposomes can be
used in conjunction with photosensitizers(69). They were
shown to have good selectivity towards tumor tissue, but
their loading capacity is limited(67). Micellar systems were
also shown to possess good selectivity, but severe side
effects such as anaphylactic shocks were reported(70). This
led to intensive research on particulate delivery systems, e.g.
nanoparticles, which may consist of polymers, metals and
ceramics that can incorporate lipophilic photosensitizers and
impart selectivity against tumor cells.
Nanoparticles represent an emerging photosensitizer
delivery system that has shown a great promise for PDT(71).
The efficiency of nanoparticles in PDT may be attributed to
the fact that PDT relies on the production of 1O2. Therefore;
it is unnecessary to release the loaded photosensitizers and
no time for biodegradation is needed, but it is only essential
that the oxygen diffuse in and out of the nanoparticles. For
example, the pores in the ceramic particle are 0.50 - 1.00 nm
in diameter, which is too small to allow the drug to escape but
are large enough to enable efficient oxygen diffusion to and
from the particles(72). The lifetime of 1O2 in aqueous media
is in the order of microseconds. As 1O2 reacts so rapidly,
PDT-induced oxidative damage is highly localized to regions
comparable to the thickness of a cell membrane(38,71). Thus,
the variability in size of the nanoparticles under 100 nm
should have a negligible effect on the delivery of 1O2.
Nanoparticles, either biodegradable, from which photosensitizer may be released within the tissues(73), or ‘‘pure
carriers” non-biodegradable nanoparticles, which entrap
photosensitizers during their activity(74) are commonly
investigated(65). There are several advantages of using
either biodegradable or non-biodegradable nanoparticles(71).
Biodegradable nanoparticles, such as the polymeric nanoparticles made from polylactide/polyglycolide copolymers(73),
are mostly aqueous in composition, whereas the silica-based
non-biodegradable nanoparticles are comprised of totally or
mostly inert silica, a medium that is probably not more reactive than water(71). Also, biodegradable polymer nanoparticles degrade readily to release the photosensitizers, whereas
the shells in non-biodegradable particles are difficult to
collapse. Compared to biodegradable polymeric carrier
systems, however, non-biodegradable nanoparticles are not
subject to microbial attack(75) and are stable to fluctuations
in temperature and pH(76). Furthermore, their size, shape,
porosity and mono-dispersibility can easily be controlled
during their preparation(68).

Based on these concepts, different nanoparticle chemistries have been investigated to determine the optimal components and the simplest structure that may be used in clinics.
Most efforts have been focused on developing a carrier with
low complexity, void of metabolic and tissue interactions, and
which fulfill the following two conditions(65): (1) is stable, at
least for the duration of action during which carriers accumulate in tumor tissue and the photosensitizers produce ROS
upon light activation, and (2) requires the simplest synthesis
route and avoids the use of targeting agents while taking
advantage of the ‘‘enhanced permeability and retention
(EPR) effect” offered by tumors(77). The EPR effect is based
on two factors. First, the capillary endothelium in malignant
tissues is more disordered and thus more permeable towards
macromolecules than the capillary endothelium in normal
tissues. This allows extravasation of circulating polymeric
nanoparticles within the tumor interstitium. Second, the lack
of tumor lymphatic drainage in the tumor bed results in drug
accumulation.

CONCLUSIONS
In this review, recent progresses on liposomes, polymeric micelles and nanoparticles as nanocarriers for PS
delivery are reviewed. Current studies indicate that nanocarriers as delivery systems may be useful for clinical applications. They have the capacity to encapsulate various drugs,
including hydrophobic compounds such as metal complexes,
gene and siRNA. Their unique core-shell architecture with
a diameter of several tens of nanometers might allow for
targeted therapy, enhanced uptake and prolonged blood
circulation. The size of these carriers may be further tuned
for efficient biodistribution within the nanocarrier range
from 10 nm up to 200 nm(65) by adjusting either the temperature of the process or the concentration of co-surfactants.
While nanocarriers allow for efficient delivery of PS, their
photodynamic activity depends on a multitude of factors,
such as the type of photoactive dye, particle size and charge,
incubation time and the nature of polymer used. In the future,
PS encapsulated in carriers made of different polymers and
functional groups with easy-to-use light device may be used
in the treatment of localized microbial infection, including
the photodynamic inactivation of microorganisms (Figure 4).
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